北京赛升药业股份有限公司 2021 年第三季度报告 一、主要财务数据 证券代码：300485 证券简称：赛升药业 公告编号：2022-032 北京赛升药业股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告 中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期增 | | 年初至报告期末 | 年初至报告期末比上年 | | --- | --- | --- | --- | --- | --- | | | | 减 | | | 同期增减 | | 营业收入（元） | 342,775,244.87 | | 11.75% | 809,479,013 ...

Financial Performance - The company reported a profit distribution plan, proposing a cash dividend of 1.68 RMB per 10 shares based on a total of 481,666,400 shares[13]. - The company's operating revenue for 2021 was ¥1,050,805,089, a decrease of 3.97% compared to ¥1,094,225,280.40 in 2020[28]. - Net profit attributable to shareholders increased by 159.69% to ¥402,270,478.69 from ¥154,903,454.53 in the previous year[28]. - The net profit after deducting non-recurring gains and losses was ¥104,338,082.65, down 15.57% from ¥123,581,325.99 in 2020[28]. - The company's total assets increased by 13.73% to ¥3,401,649,422.52 at the end of 2021, compared to ¥2,991,062,511.44 at the end of 2020[28]. - Basic earnings per share rose by 162.50% to ¥0.84 from ¥0.32 in 2020[28]. - The company reported a net cash flow from operating activities of ¥183,295,288.13, a decrease of 30.50% from ¥263,725,621.99 in the previous year[28]. - The company reported non-recurring gains of ¥297,932,396.04 in 2021, significantly higher than ¥31,322,128.54 in 2020[34]. - The company achieved operating revenue of 1,050.81 million yuan, a decrease of 3.97% compared to the previous year, while net profit attributable to shareholders increased by 159.69% to 402.27 million yuan[59]. - The total revenue for the pharmaceutical manufacturing industry was approximately ¥1,049.66 million, accounting for 99.89% of total revenue, with a year-over-year decrease of 4.05%[76]. Research and Development - New drug development is a priority, but the company acknowledges the lengthy and uncertain nature of the process, which may impact operational costs and profitability[11]. - The company is focused on enhancing R&D capabilities and optimizing project selection to improve the success rate of new drug development[12]. - The company aims for an annual R&D investment growth of over 10% as part of its strategic goals during the "14th Five-Year Plan" period[38]. - The company emphasizes research and development, collaborating with academic institutions to accelerate product development[53]. - The company has established a proprietary biopharmaceutical purification technology platform, enhancing its production capabilities[54]. - The company has developed a key technology platform for antibody drugs, focusing on the discovery and research of new anti-tumor or immune-related antibodies[73]. - The company has established a platform for peptide drug design and synthesis, completing preliminary synthesis and process research for several anti-tumor drugs[73]. - The R&D department has filed 36 patents, with 17 patents granted during the reporting period[165]. - The management team emphasized a commitment to innovation, with a budget increase of 30% for R&D in 2022[166]. Market and Competition - The marketing network covers major cities in China, but the company anticipates challenges in market expansion due to evolving market demands and intensified competition[8]. - The company recognizes the potential for product price declines due to changes in procurement systems and increased competition in the market[9]. - The company is actively monitoring industry trends and may consider mergers or collaborations to achieve strategic goals[13]. - The company is focusing on internationalization in innovation, particularly in promoting traditional Chinese medicine abroad[38]. - The market for cardiovascular drugs is expected to expand due to an aging population, with projections indicating that by 2035, the population aged 65 and above in China will reach 210 million, accounting for 22.30% of the total population[42]. - The company is expanding its market presence through strategic partnerships and investments in biotechnology firms[53]. - The company is actively expanding its market presence through new product development and clinical trials, aiming to enhance its portfolio and revenue streams[72]. Product Development and Quality - The company emphasizes the importance of product quality, with a systematic quality control system in place to mitigate risks associated with complex production processes[10]. - The company is committed to increasing investment in product quality and accelerating the development of new products to meet regulatory requirements[10]. - The company has a diverse product pipeline with a balanced revenue contribution from various products, reducing reliance on any single product[53]. - The company focuses on the research, production, and sales of injectable drugs, with key products in cardiovascular, immune, and neurological disease treatments[43]. - The company has developed five national drug standard original research products, including fibrinolysin and its injection, and is the first in China to produce several key injectable drugs[44]. - The company’s immune regulation products include "Saiseng" and "Saisong" injections, targeting conditions such as progressive muscular dystrophy and chronic hepatitis[45]. - The company has completed the production registration application for a drug aimed at patients with bleeding tendencies, currently undergoing technical review[72]. - The company has prioritized rights for contract manufacturing and sales of BXOS110 project products post-approval, expanding its strategic development layout[68]. Governance and Management - The company has established a complete and independent financial management system, with dedicated accounting personnel and independent decision-making capabilities[146]. - The company ensures compliance with governance standards and has no significant discrepancies with regulatory requirements[143]. - The company has implemented performance evaluation and incentive mechanisms for senior management, ensuring transparency in appointments[142]. - The company actively engages with investors through various channels to enhance information transparency and investor relations[141]. - The board of directors consists of 8 members, including 3 independent directors, and held 13 meetings, reviewing 51 proposals[138]. - The company has expanded its board with independent directors who bring diverse expertise, including legal and financial backgrounds, to strengthen governance[158][159]. - The company has a clear focus on enhancing its market presence and operational efficiency through ongoing research and development initiatives[160]. Social Responsibility and Community Engagement - The company actively participated in social responsibility initiatives, donating a total of 100,000 RMB to aid flood relief efforts in Henan province[196]. - The company has established a partnership with Nanying Village in Pinggu District to support local economic development and poverty alleviation efforts[198]. - The company has implemented a GMP quality management system to ensure product quality and safety[196]. - The company has actively contributed to COVID-19 relief efforts by donating supplies to affected regions[196]. Strategic Investments and Acquisitions - The company has engaged in a merger and acquisition by acquiring a 3.077% stake in a biotechnology firm for ¥20,000,000[101]. - The company plans to focus on developing vaccines and treatments for various diseases through its recent acquisitions and investments[102]. - The company has completed two strategic acquisitions in the past year, enhancing its product portfolio and market reach[166]. - The company has signed a cooperation agreement with Lin Xuefang and Zhang Yi, indicating strategic partnerships for future growth[103]. Employee Development and Training - The company has implemented a flexible online training program for employees, including various training formats such as public courses and internal training[183]. - The company emphasizes the importance of talent development, implementing specific training plans for new graduates to ensure a strong talent pipeline for future growth[128]. - The total number of employees at the end of the reporting period is 584, with 447 in the parent company and 137 in major subsidiaries[180]. - The professional composition includes 172 production personnel, 82 sales personnel, 179 technical personnel, 14 financial personnel, and 137 administrative personnel[180].

北京赛升药业股份有限公司 2021 年第一季度报告全文 北京赛升药业股份有限公司 2021 年第一季度报告 2022-029 2022 年 03 月 1 第一节 重要提示 公司董事会、监事会及除以下存在异议声明的董事、监事、高级管理人员 外的其他董事、监事、高级管理人员均保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人马骉、主管会计工作负责人马丽及会计机构负责人(会计主管人 员)栗建华声明：保证季度报告中财务报表的真实、准确、完整。 2 北京赛升药业股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 北京赛升药业股份有限公司 2021 年第一季度报告全文 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 233,134,003.59 | 167,249,354.70 | 39.39% | | 归属于上市公司股东 ...

Financial Performance - The company's revenue for Q3 2021 was CNY 342,775,244.87, an increase of 11.75% compared to the same period last year, and the year-to-date revenue reached CNY 1,212,681,679.32, up 53.26% year-on-year[3] - The net profit attributable to shareholders for Q3 2021 was CNY 52,379,695.74, representing an 18.33% increase year-on-year, while the year-to-date net profit was CNY 137,713,159.02, a 6.63% increase[3] - The basic earnings per share for Q3 2021 was CNY 0.11, up 22.22% year-on-year, and the diluted earnings per share was also CNY 0.11[4] - Total operating revenue for Q3 2021 reached CNY 1,212,681,679.32, a significant increase of 53.1% compared to CNY 791,257,671.76 in the same period last year[28] - Net profit for Q3 2021 was CNY 133,778,745.44, representing a 6.1% increase from CNY 126,247,006.57 in Q3 2020[29] - The company reported a total comprehensive income of CNY 133,581,372.59 for Q3 2021, up from CNY 126,247,006.57 in Q3 2020[31] Assets and Liabilities - The total assets as of September 30, 2021, were CNY 3,690,908,471.22, a 23.40% increase from the end of the previous year[4] - The total assets of the company as of Q3 2021 amounted to CNY 3,690,908,471.22, compared to CNY 2,991,062,511.44 at the end of Q3 2020, reflecting a growth of 23.4%[28] - The total liabilities increased to CNY 730,914,796.40, up from CNY 141,128,369.42, indicating a substantial rise in financial obligations[27] - The company's equity attributable to shareholders reached CNY 2,910,642,193.37, an increase from CNY 2,804,427,300.38 year-over-year[28] Cash Flow - The company's cash flow from operating activities for the year-to-date was CNY 82,079,575.10, down 63.72% compared to the same period last year[3] - The cash inflow from operating activities totaled CNY 1,150,837,917.77, an increase from CNY 891,367,653.51 in the previous period, representing a growth of approximately 29%[34] - The net cash flow from operating activities was CNY 82,079,575.10, down from CNY 226,249,463.81 in the previous period, indicating a decline of about 64%[34] - Cash outflow for purchasing goods and services was CNY 406,687,308.56, significantly higher than CNY 116,697,811.16 in the previous period[34] - The net cash flow from investing activities was negative at CNY -273,881,865.82, an improvement from CNY -530,418,724.81 in the previous period[35] - The company reported a cash outflow of CNY 36,152,698.13 from financing activities, compared to CNY 31,456,497.57 in the previous period, indicating a higher cash outflow[35] Research and Development - Research and development expenses for the year-to-date were CNY 80,473,801.38, an increase of 88.25% year-on-year, indicating a significant investment in R&D[12] - Research and development expenses increased to CNY 80,473,801.38, up 88.5% from CNY 42,749,087.53 in the previous year[29] Receivables and Liabilities - The company reported an increase in trading financial assets by 68.83% year-to-date, reaching CNY 857,121,656.75, due to increased short-term bank investment[8] - The company's accounts receivable increased by 53.10% year-to-date, amounting to CNY 176,394,679.01, primarily due to receivables from a consolidated subsidiary[8] - The company experienced a significant increase in contract liabilities, which rose by 3778.67% year-to-date to CNY 419,956,003.18, mainly from a consolidated subsidiary[10] Investment Income - The investment income for the year-to-date was CNY 28,692,824.28, a 162.72% increase year-on-year, driven by gains from stock sales and investment returns[13] - Cash received from investment income was 31,645,831.76 CNY, an increase of 19,405,691.44 CNY or 158.54% year-over-year, mainly from the sale of part of the company's holdings in Kang Le Wei Shi stocks and increased financial income[16] - Cash paid for investments was 81,000,000.00 CNY, an increase of 28,848,240.00 CNY or 55.32% year-over-year, indicating increased external investments[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 34,327, with the largest shareholder holding 49.51% of the shares[20] Other Financial Information - The company received CNY 28,790,292.71 in tax refunds during the period[34] - The company did not adjust the beginning balance sheet items for the new leasing standards as there were no related leasing activities[36] - The third quarter report was not audited[36]

Financial Performance - The company's operating revenue for the first half of 2021 was ¥869,906,434.45, representing a 79.54% increase compared to ¥484,520,630.90 in the same period last year[22]. - The net profit attributable to shareholders of the listed company was ¥85,333,463.28, a slight increase of 0.53% from ¥84,884,458.26 in the previous year[22]. - The net profit after deducting non-recurring gains and losses decreased by 32.89% to ¥51,614,391.46 from ¥76,915,530.41 in the same period last year[22]. - The net cash flow from operating activities was ¥44,859,289.95, down 68.45% from ¥142,201,118.48 in the previous year[22]. - Total assets at the end of the reporting period were ¥3,683,303,396.18, an increase of 23.14% from ¥2,991,062,511.44 at the end of the previous year[22]. - The net assets attributable to shareholders of the listed company were ¥2,858,136,029.58, a 1.92% increase from ¥2,804,427,300.38 at the end of the previous year[22]. - The basic earnings per share remained unchanged at ¥0.18, consistent with the previous year[22]. - The diluted earnings per share also remained unchanged at ¥0.18, consistent with the previous year[22]. - The weighted average return on net assets was 3.01%, a slight decrease from 3.13% in the previous year[22]. - The company reported a total investment income of ¥10,472,034.35, accounting for 11.06% of total profit, primarily from bank financial product returns[59]. Business Operations - The main business focuses on the research, production, and sales of injectable drugs, particularly in the fields of cardiovascular, immune, and neurological diseases[30]. - The company invested in a 45% stake in Beijing Zhongrun Weiye Investment Co., which has become a subsidiary, enhancing its presence in the medical equipment import and export sector[30]. - The primary products include "Saiseng" Thrombolytic Enzyme Injection and "Saisong" Deoxynucleotides Sodium Injection, targeting various medical conditions such as muscular dystrophy and hepatitis[31]. - The company has developed a complete procurement, production, and sales system, ensuring efficient operations[35]. - The company’s subsidiary, Sair Biological, focuses on the development and production of tablets and capsules, with six production lines in operation[32]. - The company has established a comprehensive production chain, allowing it to engage in various dosage forms, including small-volume injections and oral preparations, which mitigates risks associated with raw material price fluctuations[53]. Research and Development - The company’s research and development efforts include new products such as the K193 antibody, which has entered phase 1 clinical trials[34]. - The company is conducting clinical trials for multiple drugs, including Antianjide peptide for cancer treatment, currently in Phase I with progress on five dosage groups[41]. - The company is focusing on the development of new drugs, with several projects in various stages of clinical trials, including K3 for rheumatoid arthritis and K11 for metastatic colorectal cancer[44]. - The company has invested in R&D and established partnerships with research institutions to accelerate product development, including the acquisition of Junyuan Pharmaceutical to expand into the health industry[47]. - The company has developed a proprietary biopharmaceutical purification technology platform, enhancing its capabilities in producing biologically active macromolecules[48]. Market Position and Strategy - The company has achieved over 50% market share in cardiovascular products and immunomodulators, establishing itself as a market leader[40]. - The company aims to expand its market presence through strategic investments and partnerships in the medical and pharmaceutical sectors[30]. - The company is focusing on retaining core personnel to safeguard its R&D capabilities, as talent competition intensifies in the industry[97]. - The company is exploring potential mergers and acquisitions to enhance its market position and expand its product portfolio[196]. Financial Management and Investments - The total amount of raised funds is CNY 1,080,944,700 after deducting issuance costs of CNY 72,855,300[77]. - Cumulative investment of raised funds reached CNY 70,801,000 as of June 30, 2021, with CNY 51,285,710 remaining unused[77]. - The company has established a dedicated account for raised funds to ensure they are used exclusively for investment projects[77]. - The company has not made any significant non-equity investments[73]. - The company has a total of CNY 961,306,871.36 in other financial assets, with a fair value loss of CNY 5,336,402.96[74]. Challenges and Risks - The company faces increased policy risks in the pharmaceutical industry due to ongoing reforms and regulations, impacting market access and operational requirements[95]. - New drug development is a priority, but the company faces risks related to lengthy development cycles and market acceptance, which could impact profitability[97]. - The company anticipates challenges in market expansion and potential price declines due to increased competition and changes in healthcare policies[95]. Corporate Governance and Social Responsibility - The company is committed to social responsibility, integrating it into its business strategy and operations[107]. - Employee rights are protected in compliance with national labor laws, and the company emphasizes a harmonious labor relationship[108]. - The company has established a performance-based compensation system to incentivize employee contributions and align their interests with corporate growth[108].

北京赛升药业股份有限公司 2020 年年度报告全文 北京赛升药业股份有限公司 2020 年年度报告 2021-026 2021 年 03 月 1 北京赛升药业股份有限公司 2020 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 公司负责人马骉、主管会计工作负责人马丽及会计机构负责人(会计主管人 员)栗建华声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司已在本报告第四节第九项"公司未来发展的展望"部分对公司未来发 展 战略、2021 年经营计划及可能面对的风险因素进行了详细阐述，请投资者注 意 阅读。 公司经本次董事会审议通过的利润分配预案为：以 481666400 为基数，向 全体股东每 10 股派发现金红利 0.65 元（含税），送红股 0 股（含税），以资本公 积金向全体股东每 10 股转增 0 股。 2 $$\mathbb{H}{\overline{{\mathbb{X}}}}^{*}$$ | 第一节 ...

北京赛升药业股份有限公司 2020 年第三季度报告全文 北京赛升药业股份有限公司 2020 年第三季度报告 2020-069 2020 年 10 月 1 北京赛升药业股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人马骉、主管会计工作负责人马丽及会计机构负责人(会计主管人 员)栗建华声明：保证季度报告中财务报表的真实、准确、完整。 2 北京赛升药业股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增 | | --- | --- | --- | --- | --- | | | | | | 减 | | 总资产（元） | 2,950,466,156.88 | 2,805,502,672.29 | | 5.17% | | 归属于上市公司股 ...

北京赛升药业股份有限公司 2020 年半年度报告全文 北京赛升药业股份有限公司 2020 年半年度报告 2020-050 2020 年 08 月 1 北京赛升药业股份有限公司 2020 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人马骉、主管会计工作负责人马丽及会计机构负责人(会计主管人 员)栗建华声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司已在本报告第四节"经营情况讨论与分析"第九项"公司面临的风险 和应对措施"部分对公司可能面对的风险因素进行了详细阐述，请投资者注意 阅读。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 北京赛升药业股份有限公司 2020 年半年度报告全文 释义 | 释义项 | 指 | 释义内容 | | --- | --- | --- | | 本公司、公司、赛升药业 | 指 | 北京赛升药业股份有限公司 | | 控股股东、实际控制人 | 指 | 马骉 | | ...

[Important Notice](index=2&type=section&id=%E7%AC%AC%E4%B8%80%E8%8A%82%20%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA) This section confirms the company's management and accounting personnel's assurance of the quarterly report's accuracy and completeness, along with their legal responsibilities [Board of Directors' Statement](index=2&type=section&id=%E8%91%A3%E4%BA%8B%E4%BC%9A%E5%A3%B0%E6%98%8E) The company's Board of Directors, Supervisory Board, and senior management collectively affirm the truthfulness, accuracy, and completeness of this quarterly report and assume legal responsibility - The company's management (Board of Directors, Supervisory Board, and senior executives) jointly guarantee the **truthfulness, accuracy, and completeness** of this quarterly report and assume corresponding legal responsibilities[4](index=4&type=chunk) - The company's principal officer, the person in charge of accounting, and the head of the accounting department all declare to guarantee the **truthfulness, accuracy, and completeness** of the financial statements[5](index=5&type=chunk) [Company Profile](index=3&type=section&id=%E7%AC%AC%E4%BA%8C%E8%8A%82%20%E5%85%AC%E5%8F%B8%E5%9F%BA%E6%9C%AC%E6%83%85%E5%86%B5) This section details the company's Q1 2020 financial performance, including revenue and profit declines, strong operating cash flow, and key shareholder information [Key Accounting Data and Financial Indicators](index=3&type=section&id=%E4%B8%80%E3%80%81%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) The company experienced a Q1 2020 revenue decline of 14.32% and net profit drop of 43.19%, yet operating cash flow significantly increased by 299.18% Key Financial Indicators for Q1 2020 | Item | Current Period | Prior Period | Year-over-Year Change | | :--- | :--- | :--- | :--- | | Total Operating Revenue (Yuan) | 167,249,354.70 | 195,202,444.15 | -14.32% | | Net Profit Attributable to Shareholders (Yuan) | 25,443,560.16 | 44,784,087.10 | -43.19% | | Net Profit Attributable to Shareholders (Excluding Non-recurring Items) (Yuan) | 21,433,615.30 | 40,500,251.33 | -47.08% | | Net Cash Flow from Operating Activities (Yuan) | 35,097,216.95 | 8,792,310.69 | 299.18% | | Basic Earnings Per Share (Yuan/share) | 0.050 | 0.090 | -44.44% | | Weighted Average Return on Net Assets | 0.95% | 1.74% | -0.79% | Non-recurring Gains and Losses for Q1 2020 | Item | Amount (Yuan) | | :--- | :--- | | Gains/Losses from Entrusted Investments or Asset Management | 1,799,613.50 | | Fair Value Change Gains/Losses from Financial Assets Held for Trading | 3,192,905.66 | | Other Non-operating Income and Expenses | -274,936.97 | | Income Tax Impact | -707,637.33 | | **Total** | **4,009,944.86** | [Shareholder Information](index=4&type=section&id=%E4%BA%8C%E3%80%81%E6%8A%A5%E5%91%8A%E6%9C%9F%E6%9C%AB%E8%82%A1%E4%B8%9C%E6%80%BB%E6%95%B0%E5%8F%8A%E5%89%8D%E5%8D%81%E5%90%8D%E8%82%A1%E4%B8%9C%E6%8C%81%E8%82%A1%E6%83%85%E5%86%B5%E8%A1%A8) The company had 24,882 common shareholders, with controlling shareholder Ma Biao and related family members holding a significant combined stake - At the end of the reporting period, the company had a total of **24,882** common shareholders[12](index=12&type=chunk) Top Three Shareholders' Holdings | Shareholder Name | Shareholder Type | Holding Percentage | Number of Shares Held | | :--- | :--- | :--- | :--- | | Ma Biao | Domestic Natural Person | 49.25% | 238,464,000 | | Ma Li | Domestic Natural Person | 11.18% | 54,125,791 | | Liu Shuqin | Domestic Natural Person | 2.41% | 11,664,000 | - The top three shareholders, Ma Biao, Ma Li, and Liu Shuqin, have related party relationships: Ma Biao and Ma Li are siblings, and Liu Shuqin is their mother[14](index=14&type=chunk) [Significant Events](index=6&type=section&id=%E7%AC%AC%E4%B8%89%E8%8A%82%20%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9) This section details significant financial changes, including asset and profit shifts, the impact of COVID-19 on business, and the status of raised funds utilization [Significant Changes in Key Financial Data and Their Reasons](index=6&type=section&id=%E4%B8%80%E3%80%81%E6%8A%A5%E5%91%8A%E6%9C%9F%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%95%B0%E6%8D%AE%E3%80%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87%E5%8F%91%E7%94%9F%E9%87%8D%E5%A4%A7%E5%8F%98%E5%8A%A8%E7%9A%84%E6%83%85%E5%86%B5%E5%8F%8A%E5%8E%9F%E5%9B%A0) Significant financial changes include a 928.68% increase in fixed assets, a 258.06% surge in R&D expenses, a 45.44% drop in operating profit, and a 299.18% rise in operating cash flow - Balance Sheet Item Changes: - **Fixed Assets**: Increased by **928.68%** year-over-year, primarily due to the capitalization of construction in progress projects - **Construction in Progress**: Decreased by **93.51%** year-over-year, due to conversion to fixed assets - **Financial Assets Held for Trading**: Increased by **51.33%** year-over-year, mainly due to increased short-term bank wealth management investments[18](index=18&type=chunk) - Income Statement Item Changes: - **Research and Development Expenses**: Increased by **258.06%** year-over-year, due to the company's increased R&D investment - **Operating Profit**: Decreased by **45.44%** year-over-year, primarily impacted by reduced sales revenue and increased R&D investment - **Net Profit Attributable to Parent Company Shareholders**: Decreased by **43.19%** year-over-year, mainly due to reduced sales revenue[22](index=22&type=chunk) - Cash Flow Statement Item Changes: - **Net Cash Flow from Operating Activities**: Increased by **299.18%** year-over-year, primarily due to reduced tax and fee payments in the current period - **Net Cash Flow from Investing Activities**: Decreased by **218.28%** year-over-year, mainly due to increased purchases of short-term wealth management products in the current period[24](index=24&type=chunk) [Business Review and Outlook](index=8&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%9A%E5%8A%A1%E5%9B%9E%E9%A1%BE%E5%92%8C%E5%B1%95%E6%9C%9B) Q1 revenue declined 14.32% due to COVID-19 impacts, while the company actively supported epidemic control and disclosed key risks including policy, market, quality, R&D, and talent retention - In Q1 2020, the company achieved operating revenue of **167 million Yuan**, a year-over-year decrease of **14.32%**; net profit attributable to parent company shareholders was **25.44 million Yuan**, a year-over-year decrease of **43.19%**[24](index=24&type=chunk) - The company actively responded to the COVID-19 pandemic by urgently resuming work during the Spring Festival to produce and donate immune-modulating drugs, such as Thymosin Alpha 1 for Injection and Polysaccharide Peptide Injection, to support epidemic prevention and control[25](index=25&type=chunk) - The company completed a **$1.6 million** investment in overseas entity Curiato INC through its Hong Kong subsidiary[25](index=25&type=chunk) - The company faces major risks including: pharmaceutical industry policy risks (e.g., centralized procurement, medical insurance cost control), market development and product price reduction risks, product quality risks, new drug R&D failure risks, and core personnel loss risks[26](index=26&type=chunk)[27](index=27&type=chunk)[28](index=28&type=chunk) [Use of Raised Funds](index=11&type=section&id=%E4%BA%94%E3%80%81%E5%8B%9F%E9%9B%86%E8%B5%84%E9%87%91%E4%BD%BF%E7%94%A8%E6%83%85%E5%86%B5%E5%AF%B9%E7%85%A7%E8%A1%A8) The company has invested 652 million Yuan of its 1.081 billion Yuan raised funds, with key projects completed but regulatory filings delayed, leaving 548 million Yuan unused Overview of Raised Funds Utilization (Unit: Ten Thousand Yuan) | Item | Amount | | :--- | :--- | | Total Raised Funds | 108,094.47 | | Total Investment This Quarter | 894.82 | | Total Cumulative Investment | 65,200.07 | | Unused Raised Funds | 54,773.51 | - The "New Pharmaceutical Production Base Project" and "New Cardiovascular and Immune-Modulating Product Industrialization Project" were completed and capitalized in December 2019, but regulatory filing progress is behind schedule due to institutional reforms and the pandemic[35](index=35&type=chunk) - As of March 31, 2020, unused raised funds are held in dedicated bank accounts, time deposits, and wealth management products awaiting redemption[36](index=36&type=chunk) [Financial Statements](index=14&type=section&id=%E7%AC%AC%E5%9B%9B%E8%8A%82%20%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) This section provides the company's unaudited Q1 2020 consolidated financial statements, including the balance sheet, income statement, and cash flow statement, along with an explanation of accounting policy changes [Consolidated Financial Statements](index=14&type=section&id=1%E3%80%81%E5%90%88%E5%B9%B6%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) This section presents the company's Q1 2020 consolidated balance sheet, income statement, and cash flow statement, detailing key financial performance metrics [Consolidated Balance Sheet](index=14&type=section&id=%E5%90%88%E5%B9%B6%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) As of March 31, 2020, total assets reached 2.818 billion Yuan, total liabilities were 66.39 million Yuan, and parent company equity was 2.704 billion Yuan Key Consolidated Balance Sheet Items (March 31, 2020) | Item | Amount (Yuan) | | :--- | :--- | | **Total Assets** | **2,818,250,325.92** | | Total Current Assets | 1,611,151,832.92 | | Total Non-current Assets | 1,207,098,493.00 | | **Total Liabilities** | **66,393,021.62** | | **Total Equity Attributable to Parent Company Owners** | **2,704,263,114.95** | [Consolidated Income Statement](index=19&type=section&id=%E5%90%88%E5%B9%B6%E5%88%A9%E6%B6%A6%E8%A1%A8) Q1 2020 saw operating revenue of 167 million Yuan, a 14.32% decrease, and net profit attributable to parent company owners of 25.44 million Yuan, a 43.19% decline Key Consolidated Income Statement Items (Q1 2020) | Item | Current Period Amount (Yuan) | Prior Period Amount (Yuan) | | :--- | :--- | :--- | | Operating Revenue | 167,249,354.70 | 195,202,444.15 | | Total Operating Costs | 147,158,831.03 | 153,838,864.46 | | Research and Development Expenses | 11,957,633.10 | 3,339,538.91 | | Operating Profit | 28,624,611.60 | 52,466,497.81 | | Net Profit Attributable to Parent Company Owners | 25,443,560.16 | 44,784,087.10 | | Basic Earnings Per Share | 0.050 | 0.090 | [Consolidated Cash Flow Statement](index=24&type=section&id=%E5%90%88%E5%B9%B6%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) Q1 2020 saw operating cash flow increase by 299.18% to 35.10 million Yuan, while investing cash flow was -293 million Yuan, and financing cash flow was 15 million Yuan Key Consolidated Cash Flow Statement Items (Q1 2020) | Item | Current Period Amount (Yuan) | Prior Period Amount (Yuan) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 35,097,216.95 | 8,792,310.69 | | Net Cash Flow from Investing Activities | -293,295,337.50 | 247,974,472.74 | | Net Cash Flow from Financing Activities | 15,000,000.00 | 0.00 | | Net Increase in Cash and Cash Equivalents | -243,198,120.55 | 256,766,783.43 | [Explanation of Financial Statement Adjustments](index=28&type=section&id=%E4%BA%8C%E3%80%81%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8%E8%B0%83%E6%95%B4%E6%83%85%E5%86%B5%E8%AF%B4%E6%98%8E) The company adopted new revenue and lease accounting standards from January 1, 2020, with no adjustments to the opening financial statements - The company first adopted new revenue and lease accounting standards starting in **2020**, but this accounting policy change did not result in adjustments to relevant items in the opening financial statements for the current period[76](index=76&type=chunk)[77](index=77&type=chunk)[80](index=80&type=chunk) [Audit Report](index=31&type=section&id=%E4%B8%89%E3%80%81%E5%AE%A1%E8%AE%A1%E6%8A%A5%E5%91%8A) The company's Q1 2020 financial report remains unaudited - The company's **Q1 2020** financial report is unaudited[84](index=84&type=chunk)

北京赛升药业股份有限公司 2019 年年度报告全文 北京赛升药业股份有限公司 2019 年年度报告 2020-010 2020 年 04 月 1 北京赛升药业股份有限公司 2019 年年度报告全文 第一节重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人马骉、主管会计工作负责人马丽及会计机构负责人(会计主管人 员)栗建华声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司已在本报告第四节第九项"公司未来发展的展望"部分对公司未来发 展 战略、2020 年经营计划及可能面对的风险因素进行了详细阐述，请投资者 注意 阅读。 公司经本次董事会审议通过的利润分配预案为：以 484,166,000 为基数， 向全体股东每 10 股派发现金红利 0.62 元（含税），送红股 0 股（含税），以资 本公积金向全体股东每 10 股转增 0 股。 2 | 第一节重要提示、目录和释义 2 | | --- | | 第二节公司简介和主要财务指标 6 | | ...